ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination

Mumoli, Laura; Vescio, Virginia; Pirritano, Domenico; Russo, Emilio; Bosco, Domenico

doi:10.1007/s10072-021-05761-7

Cited by 23 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Including our case, during the current COVID-19 pandemic, there have been three cases of MOGAD occurring after SARS-CoV-2 vaccinations (19,20). In these cases, the patients developed their neurological symptoms at various times throughout their vaccinations, from 1 to 2 weeks after the first or second vaccine doses (Table 1).…”

Section: Discussionmentioning

confidence: 92%

MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a newly identified autoimmune demyelinating disorder that is often associated with acute disseminated encephalomyelitis and usually occurs postinfection or postvaccination. Here we report a case of MOGAD after mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. A previously healthy 68-year-old woman presented to our department with gradually worsening numbness on the right side of her face, which began 14 days after her second dose of an mRNA-1273 vaccination. The patient's brain MRI revealed a right cerebellar peduncle lesion with gadolinium enhancement, a typical finding of MOGAD. A neurological examination revealed paresthesia on her right V2 and V3 areas. Other neurological examinations were unremarkable. Laboratory workups were positive for serum MOG-IgG as assessed by live cell-based assays and the presence of oligoclonal bands in the cerebrospinal fluid (CSF). The patient's serum test results for cytoplasmic-antineutrophil cytoplasmic antibodies, perinuclear-cytoplasmic-antineutrophil cytoplasmic antibodies, GQ1b-antibodies, and aquaporin-4 antibodies (AQP4-IgG) were all negative. Tests for soluble interleukin (IL)-2 receptors in the serum, IL-6 in the CSF and skin pricks, and angiotensin converting enzyme tests were all unremarkable. The patient was diagnosed with MOGAD after receiving an mRNA SARS-CoV-2 vaccination. After two courses of intravenous methylprednisolone treatment, the patient's symptoms improved and her cerebellar peduncle lesion shrunk slightly without gadolinium enhancement. To date, there have only been two cases of monophasic MOGAD following SARS-CoV-2 vaccination, including both the ChAdOx1 nCOV-19 and mRNA-1273 vaccines, and the prognosis is generally similar to other typical MOGAD cases. Although the appearance of MOG antibodies is relatively rare in post-COVID-19–vaccine demyelinating diseases, MOGAD should be considered in patients with central nervous system (CNS) demyelinating diseases after receiving a SARS-CoV-2 vaccine.

show abstract

Section: Discussionmentioning

confidence: 92%

MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There have been 3 other cases of ChAdOx1 associated ADEM in the literature (Table 3 ) [ 6 – 8 ]. Symptom onset occurred between 7–14 days from vaccine administration.…”

Section: Discussionmentioning

confidence: 99%

Acute disseminated encephalomyelitis with bilateral optic neuritis following ChAdOx1 COVID-19 vaccination

et al. 2022

View full text Add to dashboard Cite

Background Acute disseminated encephalomyelitis (ADEM) is a rare immune-mediated inflammatory demyelinating disease of the central nervous system. We report a case of ADEM presenting with bilateral optic neuritis temporally associated with the ChAdOx1 vaccine against SARS-COVID19 virus. Case presentation A 36-year-old female presented with bilateral optic neuritis following her first dose of the ChAdOx1 vaccine. Initial MRI Brain showed evidence of demyelination within the subcortical white matter, with no radiological involvement of the optic nerves. Visual evoked potentials were consistent with bilateral optic neuritis which was confirmed radiologically on follow up MRI. She was treated with intravenous steroids with improvement both in symptoms and radiological appearance. A pseudo-relapse occurred which was treated with a further course of intravenous steroids followed by an oral taper. The clinical, radiological and serological results were most consistent with diagnosis of ADEM. Conclusions ADEM is an exceedingly rare complication of ChAdOx1 vaccine despite millions of doses. While it is imperative clinicians remain aware of neurological complications of vaccines, the importance of vaccination to control a pandemic should not be undermined.

show abstract

“…Recently, an anti-myelin oligodendrocyte glycoprotein (MOG) antibody-positive acute disseminated encephalomyelitis (ADEM) caused by ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) was reported in Neurological Sciences [ 1 ]. Although this is rare, we report a severe case of ADEM anti-MOG antibody positive with BNT162b2 CoV-19 mRNA vaccine (Pfizer).…”

mentioning

confidence: 99%